Eric Topol (35:30): Yeah, I think the way you prep the patients who go for it is so critical because I have so many patients I know you have who have had to go through all these extra tests, biopsies and whatnot, and came at everything negative, but the anxiety they went through was profound
Looking ahead, 2026 is expected to mark a significant expansion of more real-world trials, demonstrating evidence from everyday clinical practice
BPC-157 for Gastroparesis Research Mechanism & Evidence Animal models consistently demonstrate that BPC-157 (Body Protection Compound-157) accelerates gastric emptying in induced gastroparesis
Ideal for metabolic, endocrinology, and obesity research
Instructions Instruct patients to administer BYETTA as a subcutaneous injection in the thigh, abdomen, or upper arm at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart)